All of the Above (E) is Correct for Shigella
All five statements (A through D) accurately describe key features of Shigella infection, making option E the correct answer.
Detailed Analysis of Each Statement
A) Low Inoculum Transmission - TRUE
Shigella is transmitted by an extremely small bacterial load, requiring only 10-200 viable organisms to cause infection 1. This exceptionally low infectious dose makes Shigella highly contagious through person-to-person spread, particularly in settings like childcare facilities where 59% of Shigella-associated outbreaks occur 1. The low inoculum requirement explains why secondary transmission is so efficient and why outbreaks spread rapidly in institutional settings.
B) Classic Dysentery Presentation - TRUE
Shigella characteristically causes bacillary dysentery with the complete constellation of symptoms listed: fever, nausea, vomiting, abdominal pain, diarrhea (often bloody), and tenesmus 2, 3, 4. The infection typically begins with watery diarrhea that progresses to frequent small-volume bloody stools with mucus—the hallmark of dysentery 2. In one pediatric study, 96% of hospitalized children had blood and mucus in stools, though 32% initially presented with watery diarrhea for 1-3 days before developing frank dysentery 5.
C) CNS Manifestations from Neurotoxin - TRUE
Shigella is associated with central nervous system manifestations, particularly in children. In a detailed study of 53 hospitalized children with shigellosis, 45% developed CNS manifestations 5. While historically attributed to Shiga neurotoxin (particularly from S. dysenteriae type 1), recent evidence suggests Shigella's neuroinvasive potential may contribute to neurological complications including peripheral neuropathy and has been linked to Guillain-Barré syndrome 6. The CNS complications can include seizures, altered mental status, and encephalopathy.
D) Treatment with Co-trimoxazole or Quinolone for 3 Days - TRUE (with important caveats)
The 2017 IDSA guidelines recommend azithromycin, ciprofloxacin, or ceftriaxone as first-line agents for Shigella, with TMP-SMX (co-trimoxazole) or ampicillin as alternatives if the isolate is susceptible 1. The FDA label for co-trimoxazole specifically lists shigellosis as an indication, recommending 5 days of treatment (not 3 days) 7. Historical literature from 1988 cited TMP-SMX or quinolones as treatment of choice 2.
Critical caveat: Fluoroquinolone resistance is now widespread. The IDSA guidelines specifically warn clinicians to avoid prescribing fluoroquinolones if the ciprofloxacin MIC is ≥0.12 μg/mL, even if reported as susceptible 1. Resistance patterns have evolved dramatically—strains previously susceptible to common antibiotics are now increasingly resistant to cephalosporins, fluoroquinolones, and macrolides 8.
Important Clinical Considerations
Empiric therapy should be reserved for: ill patients with fever, bloody diarrhea, and bacillary dysentery syndrome (frequent scant bloody stools, fever, cramps, tenesmus) 1
Current resistance patterns: Recent studies show high resistance to traditional agents like ampicillin (83-95%), chloramphenicol (91%), and co-trimoxazole (66%) in some regions 5, 8, making susceptibility testing essential
Duration discrepancy: While the question states "3 days," FDA labeling and IDSA guidelines recommend 5 days for shigellosis 7. The 3-day duration may reflect older practice patterns or abbreviated courses in some settings
Complications beyond dysentery: Beyond GI symptoms, shigellosis can cause renal failure (25%), respiratory manifestations (17%), and subacute intestinal obstruction (5%) 5
The answer is E—all statements apply to Shigella, though treatment duration is more accurately 5 days per current guidelines, and antibiotic selection must account for local resistance patterns 1, 7.